The study aims at finding alternative interventions for the prevention ofE. coli infection in piglets so as to boost farmers＇ benefits and improve environment in the area. Data were collected from one experimental gr...The study aims at finding alternative interventions for the prevention ofE. coli infection in piglets so as to boost farmers＇ benefits and improve environment in the area. Data were collected from one experimental group consisting of 210 small pig holder farms and one control group of 70 farms. All of 280 litters and sows were analyzed and the techniques of early vaccination at 60-80 d of pregnant （time 1） were applied and repeated after 10 d with E. coli vaccine to produce antibodies through milk. The percentage of piglets with diarrhea caused by E. coli significantly decreased from 75.7% to 18.9%. Injection of E. coli vaccine for the pregnant sows created antibodies for young piglets through colostrums. The treatment of E. coli cost 45,420 Vietnam Dong （VND） per litter in the experimental group and that was 156,000 VND/litter in the control group. Use of betel-bokashi （bio-product as plant antibiotics and Lactobacillus） to treat piglet diarrhea was proved safe and effective. Litter size and average weight at birth and weaning were improved significantly （P 〈 0.05）. The average weaned weight of piglets and sows were 11.2 kg and 118.6 kg in the experimental group, compared to 9.4 kg and 89.9 kg in the control group, respectively. Piglets in the experimental group had good health, no diarrhea and a shorter weaning time （2 d） and mating interval 2.22 days earlier than those in the control group. The average profit of 210 households was significantly higher in the experiment group： feed-cost was much lower than that in the control group. Small-holder farms implementing the experiments of applying the techniques received more financial profit, which was 1,502,000 VND per year per sow, while those who did not apply the techniques gained only 223,000 VND per year per sow.展开更多
AIM： To evaluate a low cost Indian recombinant hepatitis B vaccine GeneVac-B for its immunogenicity and safety in comparison to Engerix B and Shanvac B vaccine in high risk newborn infants born to （hepatitis B surfa...AIM： To evaluate a low cost Indian recombinant hepatitis B vaccine GeneVac-B for its immunogenicity and safety in comparison to Engerix B and Shanvac B vaccine in high risk newborn infants born to （hepatitis B surface antigen） HBsAg positive mothers.METHODS： A total of 158 infants were enrolled in the study. Fifty eight infants were enrolled in the GeneVac-B group while 50 each were included for Engerix B and Shanvac B groups. A three-dose regimen of vaccination; at birth （within 24 h of birth）, 1st mo and 6 too. were adopted with 10 μg dosage administered uniformly in all the three groups. Clinical and immunological parameters were assessed for safety and immunogenicity of the vaccines, in all the enrolled infants.RESULTS： Successful follow up until seven months of age was achieved in 83% （48/58） for GeneVac-B, 76% （38/50） and 64% （32/50） for Engerix B and Shanvac B groups respectively. 100% seroconversion and seroprotection was achieved in all the three groups of infants. The geometric mean titers of anti-HBs one month after the completion of three dose of vaccination were 90.5, 80.9 and 72.5 mTU/mL in GeneVac-B, Engerix B and Shanvac B vaccine group respectively. Furthermore the level of anti-HBs increases with age of babies who were born to HBsAg positive mothers. The GMT values of anti-HBs were 226.7, 193.9 and 173.6 mIU/mL respectively in GeneVac-B, Engerix B and Shanvac B groups one year after the completion of the three doses of vaccine. No systemic reactions were reported in infants during the entire vaccination process of GeneVac-B and the other two vaccines. Clinical safety parameters remained within the normal limits throughout the study period.CONCLUSION： The study concludes that there is no significant difference between the three recombinant hepatitis B vaccines. Administration of these vaccines within 24 h of birth to babies, born to HBsAg positive mothers will reduce the incidence of HBV infection.展开更多
文摘The study aims at finding alternative interventions for the prevention ofE. coli infection in piglets so as to boost farmers＇ benefits and improve environment in the area. Data were collected from one experimental group consisting of 210 small pig holder farms and one control group of 70 farms. All of 280 litters and sows were analyzed and the techniques of early vaccination at 60-80 d of pregnant （time 1） were applied and repeated after 10 d with E. coli vaccine to produce antibodies through milk. The percentage of piglets with diarrhea caused by E. coli significantly decreased from 75.7% to 18.9%. Injection of E. coli vaccine for the pregnant sows created antibodies for young piglets through colostrums. The treatment of E. coli cost 45,420 Vietnam Dong （VND） per litter in the experimental group and that was 156,000 VND/litter in the control group. Use of betel-bokashi （bio-product as plant antibiotics and Lactobacillus） to treat piglet diarrhea was proved safe and effective. Litter size and average weight at birth and weaning were improved significantly （P 〈 0.05）. The average weaned weight of piglets and sows were 11.2 kg and 118.6 kg in the experimental group, compared to 9.4 kg and 89.9 kg in the control group, respectively. Piglets in the experimental group had good health, no diarrhea and a shorter weaning time （2 d） and mating interval 2.22 days earlier than those in the control group. The average profit of 210 households was significantly higher in the experiment group： feed-cost was much lower than that in the control group. Small-holder farms implementing the experiments of applying the techniques received more financial profit, which was 1,502,000 VND per year per sow, while those who did not apply the techniques gained only 223,000 VND per year per sow.
文摘AIM： To evaluate a low cost Indian recombinant hepatitis B vaccine GeneVac-B for its immunogenicity and safety in comparison to Engerix B and Shanvac B vaccine in high risk newborn infants born to （hepatitis B surface antigen） HBsAg positive mothers.METHODS： A total of 158 infants were enrolled in the study. Fifty eight infants were enrolled in the GeneVac-B group while 50 each were included for Engerix B and Shanvac B groups. A three-dose regimen of vaccination; at birth （within 24 h of birth）, 1st mo and 6 too. were adopted with 10 μg dosage administered uniformly in all the three groups. Clinical and immunological parameters were assessed for safety and immunogenicity of the vaccines, in all the enrolled infants.RESULTS： Successful follow up until seven months of age was achieved in 83% （48/58） for GeneVac-B, 76% （38/50） and 64% （32/50） for Engerix B and Shanvac B groups respectively. 100% seroconversion and seroprotection was achieved in all the three groups of infants. The geometric mean titers of anti-HBs one month after the completion of three dose of vaccination were 90.5, 80.9 and 72.5 mTU/mL in GeneVac-B, Engerix B and Shanvac B vaccine group respectively. Furthermore the level of anti-HBs increases with age of babies who were born to HBsAg positive mothers. The GMT values of anti-HBs were 226.7, 193.9 and 173.6 mIU/mL respectively in GeneVac-B, Engerix B and Shanvac B groups one year after the completion of the three doses of vaccine. No systemic reactions were reported in infants during the entire vaccination process of GeneVac-B and the other two vaccines. Clinical safety parameters remained within the normal limits throughout the study period.CONCLUSION： The study concludes that there is no significant difference between the three recombinant hepatitis B vaccines. Administration of these vaccines within 24 h of birth to babies, born to HBsAg positive mothers will reduce the incidence of HBV infection.
